logo
Plus   Neg
Share
Email

Vertex Pharma: NHS England To Expand Reimbursement Agreement To Include KAFTRIO

Vertex Pharmaceuticals Incorporated (VRTX) has expanded its reimbursement agreement with NHS England for the company's cystic fibrosis medicines to include KAFTRIO, in a combination regimen with KALYDECO 150 mg. The expanded agreement includes reimbursed access to Vertex's currently licensed medicines - KALYDECO, ORKAMBI and SYMKEVI, as well as the triple combination therapy if approved.

The European Medicines Agency's Committee, CHMP, recently adopted a positive opinion for KAFTRIO in a combination regimen with KALYDECO 150 mg to treat people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation or two F508del mutations in the cystic fibrosis transmembrane conductance regulator gene.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT